Summary Germline mutations of the BRCA2 gene on chromosome 13q12-ql3 predispose to the development of early-onset breast cancer and ovarian cancer. Loss of heterozygosity detected using chromosome 1 3q markers in the vicinity of BRCA2 is observed in most cancers arising in carriers of germline BRCA2 mutations and also in 30-50% of sporadic breast and ovarian cancers. However, somatic mutations of BRCA2 are extremely rare in sporadic cancers. We have examined the hypothesis that expression of the BRCA2 gene may be suppressed in sporadic breast cancers by a mechanism that is associated with increased methylation of cytosine residues in the promoter region. Using a Hpall/Mspl digestion-polymerase chain reaction based assay, the presence of 5-methylcytosine in three CpG dinucleotides within the BRCA2 promoter was assessed in 18 breast or ovarian cancer cell lines, in an SV40 large T antigen immortalized cell line derived from normal breast epithelial cells, in 64 primary sporadic breast cancers and peripheral blood leucocytes from these cases and in a number of other normal human tissues. Methylation was not detected in any of the tissues examined, suggesting that this mechanism of transcriptional repression is unlikely to explain the absence of somatic mutations in sporadic cancers.
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Germline mutations of the BRCA2 gene on chromosome 13ql2-13 predispose to the development of early-onset breast cancer and ovarian cancer (Wooster et al, 1995) . Most germline mutations in BRCA2 are predicted to result in truncation (Wooster et al, 1995; Miki et al, 1996; Tavtigian et al, 1996) and hence inactivation of critical functions of the encoded protein. Tumours arising in carriers of BRCA2 germline mutations usually exhibit loss of heterozygosity (LOH) of chromosome 13q polymorphic markers flanking BRCA2. The allele lost is the wild-type allele inherited from the non-mutation carrying parent , a pattern that is characteristic of a tumour-suppressor gene and that is predicted to result in the absence of the functional protein in the tumour cell.
In addition to germline mutations that confer susceptibility to neoplasia, many cancer predisposition genes including RB] (T'Ang et al, 1988), p53 (Nigro et al, 1989) , VHL (Shuin et al, 1994) , NF-I (Li et al, 1992) , NF-2 (Lekanne Deprez et al, 1994) , APC (Powell et al, 1992) , MTS] (Caldas et al, 1994) and WTI (Gessler et al, 1994) are somatically mutated in sporadic cancers. These somatic mutations are usually associated with a high frequency of LOH in the vicinity of the susceptibility gene in the relevant sporadic cancers. Loss of heterozygosity at the BRCA2 locus has been observed in 30-40% of sporadic primary breast cancers Cleton Jansen et al, 1995; Kerangueven et al, 1995) and in approximately 50% of sporadic ovarian cancers (Yang Feng et al, 1993; Takahashi et al, 1996) . However, exhaustive analyses of many sporadic breast, ovarian and other cancers have indicated that somatic mutations in BRCA2 are very rare (Foster et al, 1996; Lancaster et al, 1996; Miki et al, 1996; Takahashi et al, 1996; Teng et al, 1996) . For certain tumour-suppressor genes an alternative, epigenetic mechanism of inactivation within tumour cells has been proposed. In some cancers, normally unmethylated cytosine residues within or near the promoter region of genes such as MTSJ (pl6INK4a) (Gonzalez Zulueta et al, 1995) , RBI (Ohtani Fujita et al, 1993) , E-cadherin (Yoshiura et al, 1995) and VHL (Herman et al, 1994) become methylated. The altered methylation status is transferred to daughter cells as a stable epigenetic change. Although the functional consequences of this change in methylation status are not fully understood, it is believed to be associated with and probably causally implicated in transcriptional repression of the tumoursuppressor gene. In such cancers, the requirement for somatic mutations is thought to be obviated by a substantial reduction in transcript levels of the tumour-suppressor gene. The rarity of somatic mutations in BRCA2 has therefore prompted us to examine the methylation status of a CpG island in the BRCA2 promoter region in normal and neoplastic tissues.
MATERIALS AND METHODS
DNA and RNA were isolated by conventional methods. To evaluate methylation of the cytosine within the CpG dinucleotide of HpaIllMspI sites within the BRCA2 promoter, each fragment was amplified from 100 ng of genomic DNA after (a) digestion of the test DNA with HpaII, (b) conditions.) CCGG sequences are digested equally efficiently by MspI and HpaII. However, CmeCGG sequences are digested by MspI but not HpaIl. Therefore, in the absence of pretreatment with a restriction enzyme, PCR amplification will proceed over the intact HpaII/MspI site. At an unmethylated HpaII/MspI site, both enzymes will digest efficiently, cleave the DNA segment between the PCR primer sequences and prevent PCR amplification. At a methylated HpaIYMspI site, MspI will again digest efficiently and inhibit the subsequent PCR. However, HpaII digestion will be inhibited and hence amplification of the fragment in the PCR should be successful.
To control for variations in the quality of test DNA and fluctuations in the efficiency of the PCR, an additional pair of primers that amplify a segment of BRCA2 exon 11 was included in each PCR. This fragment does not include a HpaIlYMspI restriction site and therefore should amplify under all conditions.
The sequences of the primers used in these analyses were:
5'-TGTCAGTTCATCATCTTCCATAAA-3' control for site 3 -as control for site 1.
The PCR conditions for all three sets of primer pairs were as follows: the first ten cycles constituted a 60°C to 50°C touchdown PCR (two cycles each at annealing temperatures 60°C, 58°C, 56°C, 54°C and 52°C) and subsequently 18 cycles of 1 min at 94°C (denaturation), 1 min at 50'C (annealing) and 1 min at 72°C (extension). The products were electrophoresed on 4% (site 1) or 2% (sites 2 and 3) Metaphor agarose gels containing ethidium bromide and visualized over UV light. In some experiments, the PCR primers were end labelled with [T32P]ATP using T4 polynucleotide kinase before incorporation into the PCR. The products of these amplifications were electrophoresed on 6% denaturing polyacrylamide gels and analysed using a Molecular Dynamics phosphorimager and Image Quant software.
For the analysis of BRCA2 expression, 1 ig of RNA from each of the cell lines was used to generate cDNA by reverse transcription (using a commercially available kit). A 1 ,l aliquot of the resulting cDNA was amplified in a PCR in which two pairs of primers were present. The sequences of the primers used were:
The products of the RT-PCR were electrophoresed on 2% agarose gels and then blotted by capillary transfer onto HybondN+ for 16 h in 0.4 M sodium hydroxide. The membranes were hybridized to two probes, one to detect actin and one to detect BRCA2. The sequences of the probes were:
The results were analysed using the phosphorimager and software as above.
RESULTS
Identification of a CpG island close to the 5' end of BRCA2 Genomic DNA sequence at the 5' end of the BRCA2 gene was identified from approximately one megabase of DNA sequence flanking and including BRCA2. This sequence is available at ftp://ftp.sanger.ac.uk/pub/human/sequences/1 3q, ftp://genome.wustle.edu/pub/gscl/brca2 and Genbank accession number Z73360. Within a 1.1-kb region extending from -380 to + 700 (with 0 being the transcriptional start site of BRCA2; Figure 1 ), the G + C content exceeds 60% and there is an elevated CpG/GpC ratio (Bird, 1986) . The high density of CpG dinucleotides and the location of this region are characteristic of the 'CpG islands' that are found in the vicinity of the transcriptional start site of approximately 60% of genes (most known 'housekeeping' and some tissue-specific genes) (Bird, 1986) . This 1.1-kb region also contains short sequences corresponding to SPI, USF, AP2 and CP2 transcription factor recognition sites, which are often found within the promoters of genes. However, no TATA or CAAT box was observed.
Analysis of methylation status in the BRCA2 CpG island Seven HpaIVMspI restriction endonuclease sites (CCGG) were identified within the CpG island at the 5' end of BRCA2, and oligonucleotide PCR primers were designed to amplify each site independently. However, because of the high G + C content of the DNA, only three of these fragments amplified successfully in the PCR.
Representative examples of results obtained from these studies are shown in Figure 2 . At all three HpaIVMspI sites within the CpG island, methylation was not detected in peripheral blood leucocytes from the two sporadic breast cancer cases illustrated. In the tumours from these two cases the pattern of PCR amplification is identical, suggesting that methylation is not present in neoplastic cells either. Similar studies were performed on 64 primary sporadic breast cancers and matched leucocyte DNAs, on 18 breast and ovarian cancer cell lines, on one cell line derived from normal breast epithelial cells that had been immortalized with a temperature sensitive SV40 large T antigen and on samples from normal breast, normal bladder, normal colon and normal liver. In no sample was the presence of 5-methylcytosine detected at any of the three sites observed. Haematoxylin and eosin (H + E)-stained 10-gm sections taken from the fragments of primary tumour used in these experiments were reviewed and demonstrated that 49 were composed of at least 50% tumour cells. This set of breast cancers has been previously studied and showed allele loss on chromosome 13q in 30% of cases (CletonJansen et al, 1995) .
To evaluate the sensitivity of the assay, the methylation status of a HpaIVMspI site in exon 23 of BRCA2 was examined. Predigestion with MspI abolished PCR amplification of the fragment containing this restriction site. However, digestion with HpaII left the site intact, permitting PCR amplification (Figure 3) . The results indicate that this site within the coding sequence of BRCA2 is methylated and therefore that the assay is sensitive to the methylation status. Figure 1 The sequence of the 5' CpG island associated with the BRCA2 gene. CpG dinucleotides are indicated by an asterisk, putative Spl recognition sites are underlined and Hpall/Mspl restriction sites are boxed. The high G + C content (62% compared with 30% in total genomic DNA), the increased ratio of CpG-GpC (1:1 compared with 1:5 in total genomic DNA) and the presence of several transcription factor recognition sites suggest that this region is involved with promoter functions despite the lack of classic TATA, CAAT and initiator sequences Figure 3 (A) Phosphorimager traces of a tumour DNA subjected to the methylation assay at each of the three restriction enzyme sites within the BRCA2 promoter. The PCR is unable to amplify across any of the restriction sites (S) when the DNA has been digested with Mspl or Hpall, indicating that the CpG dinucleotides in this region are not methylated. The control band (C) is present in each case showing that a negative result is not due to a failed PCR. (B) Phosphorimager traces of a blood/tumour pair subjected to the methylation assay at a CCGG site in exon 23 of BRCA2. The results indicate that the CpG dinucleotide in this Hpall/Mspl site is methylated, as the Mspl digestion is able to cleave the site but digestion with Hpall leaves the site intact in both the blood and the tumour DNA
C*G C C C A C C C A A A C A T G A G C T G G A G C A A A A A G A A A G G GAT GGGGG ACTT G GA GT AG GCAT A,GGGGC*GGCC CCT C C A A G C A G G G T G G C C T G G G A C T C T T A A G G G T C A G C*G A GA A GA G A A C A C A C A C T C C A A A T C C C*G C T T T A T T C*G G T C A G A T A C T G A C*G G T T G G G A T G C C T G A C A A G G A A T T T C C T T T C G*C C A C A C T G A G A A A T A C C C*G C
A G C*G G C C C A C C C A G G C C T G A C T T IC C*G GIC T G G T G C*G T G T G C T G C G T G T C*G C*G T C A C*G G C*G T C A C*G T G G C C A G C*G C*G G G C T TNG T G G C*G C*G A G C*G T C T G A A A C T A G G C*G G C A G A G C*G G A G C C*G C T G T G G C A C T C T G C*G C C T C T C T G C*G C C T C*G G G T G T C T T T T C*G G C*G G T G G G T C*G C C*GIC C*G GIG A G A A G C G T G A G G G G A C A G A T T T G T G AIC C*G GIC*G C*G G T T T T T G T CAG CTT A C TIC C*GG CCAA AA AAGA A CT GC GCCT C T GG AGC*GGGT T AGTGGT GGT GGT AGT GGGTT GGGAC*GA G C*G C*G T C T T C C*G C A G T C C C A G T C C A G C*G T G G C*G G G G G A G C*G C C T C A C*G C IC C*G G1G T C*G C C T G C C*G C*G G C T T C T T G C C C T T T T GT CT C T G C C A A C C CC C A C C C A T G C C T GA G A G A A A G G T C C T T G C C C*G A A G G C A A A T T T T C*G C C A A G CA A AT T C*GA GC C CC*GC CC C T T C C CT GG G T CT C C A T T T C C C*G C C TIC C*G GICIC C*G GIC C T T T G G G C T C C*G C C T T C
Expression of BRCA2
We have examined expression of BRCA2 in the breast and ovarian cancer cell lines using reverse transcription polymerase chain reaction (RT-PCR) assay for BRCA2 alone and an RT-PCR assay for BRCA2 in competition with actin (the competition for PCR reagents between primers for BRCA2 cDNA with primers for actin cDNA in the RT-PCR is equivalent to normalizing variations in loading of RNA between lanes on a Northern blot by hybridization with an actin probe). The results show that there is variation in the expression of BRCA2 (Figure 4) . Indeed, in one ovarian cancer cell line, we were unable to detect BRCA2 expression in BRCA2-actin competitive RT-PCR assays using primers in exons 10 and 11, exons 11 and 14, and exons 25 and 27. However, using primers in exons 1 and 3, we were able to detect a small amount of BRCA2 product (10-to 50-fold less than in the other cell lines tested possible that examination ofjust three CpG dinucleotides does not adequately reflect the methylation status of the more than 50 CpG dinucleotides within the BRCA2 CpG island. However, in previous studies of MTS1, RBI, E-cadherin and VHL (Ohtani Fujita et al, 1993; Herman et al, 1994 Herman et al, , 1995 Yoshiura et al, 1995) , increases in methylation of the promoter regions in cancers were associated with increases in methylation at all the CpG dinucleotides studied. (Cropp et al, 1993) and no somatic mutations of BRCAJ have yet been reported in sporadic breast cancers, with only a few in ovarian cancers Hosking et al, 1995; Merajver et al, 1995) .
The hypotheses that have been proposed to explain these observations fall into two major categories. One set makes the assumption that the losses of heterozygosity observed in sporadic breast and ovarian cancers on chromosomes 17q and 13q are directed at BRCAI and BRCA2 respectively. Thus, somatic mutations in BRCAI and BRCA2 are still to be discovered or an epigenetic mechanism substitutes for somatic mutation. The present study indicates that methylation-based transcriptional repression is unlikely to be responsible for inactivation of the retained allele. The second group of hypotheses assumes that the allele losses on chromosomes 17q and 13q are not directed at BRCAJ and BRCA2, respectively, but at other genes in the region. While this is plau- 
